As predicted, PlGF therapy rescued the maternal preeclampsia phenotype, thus decreasing blood pressure, albuminuria, and glomerular endothelial damage (Figure 3, B–G, and Supplemental Figure 3, C and D). The gene discussed is PGF; the disease is preeclampsia.